Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03223272 · ClinicalTrials.gov registry record · Phase 2
Mechanisms of Refractory Hypertension (Reserpine)
A Phase 2 study, sponsored by University of Alabama at Birmingham.
- Completed
- Registry status
- Phase 2
- Development phase
- 7
- Enrollment target
NCT03223272 is a Phase 2 study that has completed, run by University of Alabama at Birmingham. The registered enrollment target is 7 participants.
The verdict
NCT03223272, a Phase 2 study, has completed, sponsored by University of Alabama at Birmingham.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 7 participants
- Enrollment target
Study Summary
The study is deigned to determine if refractory hypertension is attributable to heightened sympathetic tone by quantifying the antihypertensive benefit of reserpine, a sympatholytic agent, in patients failing other classes of antihypertensive agents.
Interventions
- DRUG Reserpine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2015-07-23 |
| Est. Completion | 2020-01-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03223272
The ClinicalTrials.gov registry entry for NCT03223272 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Reserpine is the first listed.
NCT03223272 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03223272 about?
NCT03223272 is a clinical study titled "Mechanisms of Refractory Hypertension (Reserpine)". The study is deigned to determine if refractory hypertension is attributable to heightened sympathetic tone by quantifying the antihypertensive benefit of reserpine, a sympatholytic agent, in patients failing other classes of antihypertensive agents.
What is the current status of trial NCT03223272?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 7 participants. The study started on 2015-07-23. Estimated completion is 2020-01-31.
What interventions are being tested in trial NCT03223272?
The interventions under investigation include: Reserpine (DRUG).
Who is sponsoring clinical trial NCT03223272?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.